CRISPR Therapeutics AG Common Shares (CRSP)

FairStock Score: 30/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach CRISPR Therapeutics as a Graham-style analyst, asking first whether there is a proven business and a margin of safety. The company is developing gene-based medicines using its CRISPR/Cas9 platform, with programs in hemoglobinopathies and CAR T therapies. That is promising science, but the financial record is that of a research enterprise, not a self-sustaining business. FairStock's Lynch category is none because it has lost money in each of the last four years. Revenue has been erratic: fiscal year 2023 brought $371.2M, fiscal year 2024 $37.3M, and fiscal year 2025 just $3.5M. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $10.2M and net loss was $91.2M, or EPS -$0.94. In fiscal Q2 2025, the quarter ended 2025-06-30, revenue was $892,000 and net loss was $208.5M. The latest quarter shows some improvement, but it is still deeply loss-making. FairStock's FCF yield is -7.7% on trailing free cash flow of -$373.8M; FairStock's ROE is -26.10% and ROCE is -14.20%. At the 2026-10-13 close of $50.10, the FairStock P/B is 2.77 and P/E is negative. FairStock's Altman Z-score is 2.94, and D/E is 0.45, suggesting no immediate balance-sheet distress, but FairStock's Piotroski is 4/9 and its Score is 30/100, showing weak fundamentals. The possible moat is the platform and know-how, but the financials do not yet prove pricing power or durable earnings. Without profits or stable cash flow, valuation rests on scientific optionality. I would require a much larger margin of safety before calling the price attractive.

In plain English: CRISPR Therapeutics is a biotechnology company trying to use gene editing to treat serious diseases. It is not making a profit yet, has lost money in each of the last four years, and burns cash, though its most recent quarter had more revenue and a smaller loss than a year earlier. At $50.10, the stock looks expensive relative to its current sales and losses because the price depends mostly on future medical success, not today's financial results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer